Novo Nordisk shares positive results from COMBINE 3 phase 3a trial

Betsy Goodfellow | January 10, 2024 | News story | Research and Development Diabetes, IcoSema, Novo Nordisk, clinical trial, diabetes 

Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly IcoSema, a fixed-ration combination treatment consisting of basal insulin icodec and semaglutide.

The trial was a 52-week, open-label treat-to-target trial which assessed the efficacy and safety of once-weekly IcoSema compared to once-daily insulin glargine U100 and insulin aspart (injected 2-4 times each day during mealtimes), dosed with or without oral glucose-lowering medications. The trial included 679 people with type 2 diabetes inadequately controlled currently being treated with daily basal insulin.

The trial met its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 52 with once-weekly IcoSema compared with treatment with insulin glargine U100 and insulin aspart.

Martin Holst Lange, executive vice president for Development at Novo Nordisk, commented: “We are very pleased to share the first phase 3a results for once-weekly IcoSema. The results demonstrate the potential of IcoSema to simplify insulin intensification by reducing the injection burden to a single injection per week compared to around 28 injections per week for people with type 2 diabetes inadequately controlled on basal insulin while providing glycaemic control as well as weight benefits and lower rates of hypoglycaemia.”

Betsy Goodfellow

Related Content

Eli Lilly shares positive results from phase 3 VIVID-1 trial of Crohn’s disease treatment

Eli Lilly has announced results from its pivotal phase 3 VIVID-1 study, which assessed patients …

GSK shares positive results from phase 3 asthma trials

GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which …

J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study

Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance …

Latest content